Trinity Biotech PLC
TRIBTrinity Biotech PLC in brief
Trinity Biotech PLC is a listed company in the Diagnostics and Research industry, based in Ireland. Its market value was $8 M on 1 August 2026, which makes it the 26,221st largest listed company in the world and the 44th largest in Ireland on this site. In the year to December 2024 it had sales of $62 M and a net loss of $32 M. Its largest product and service lines by sales in 2025 were Clinical laboratory goods (72%), Point-of-Care (18%) and Clinical laboratory services (9%). By market, the largest shares of its 2025 sales came from Americas – unused tax losses (56%), Asia / Africa (35%) and Ireland (34%). Its shares trade under the symbol TRIB (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Trinity Biotech PLC
We were incorporated in Ireland in 1992 as a private limited company and re-registered as a public limited company in July of that year. In October 1992 we completed an initial public offering of our securities in the United States and our ADS have traded on the Nasdaq Global Market since that time under the symbol “TRIB”.
The principal offices of our company are located at IDA Business Park, Bray, County Wicklow, Ireland. The Group has expanded its product base through internal development and acquisitions.
We are a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. Following the acquisition of the biosensor assets of Waveform Technologies Inc. in 2024, we have been developing a range of biosensor devices and related services, beginning with a continuous glucose monitoring product. Through our subsidiaries, we develop, acquire, manufacture and market medical diagnostic products for the clinical laboratory and point‑of‑care segments of the diagnostic market. Our products are used to detect autoimmune, infectious and sexually transmitted diseases, disorders of the liver and intestine, and to monitor markers for diabetes. We market our portfolio of several hundred products to customers in approximately 100 countries around the world through our own sales force and a network of international distributors and strategic partners.
From the company's annual report filed with the US SEC: read the report
Trinity Biotech PLC timeline
- 1992
- 🔔· approximateInitial public offering on Nasdaq
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Trinity Biotech PLC from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Ireland: #61 (Jan 2020) · #65 (Jan 2021) · #62 (Jan 2022) · #50 (Dec 2022) · #50 (Jul 2023) · #49 (Jan 2024) · #8 (Mar 2026) · #44 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.1×
- Price / book
- —
- Free cash flow yield
- -57.4%
- Net margin (TTM)
- -51.6%
- Operating margin
- -34.4%
- Return on equity
- —
- Liabilities / assets
- 134.1%
- Net debt
- $-5M
- Revenue growth
- +8.3%
- R&D / revenue
- 7.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $62M | +8.3% | $-21M | $-32M | -51.6% |
| Dec 2023 | $57M | -9.1% | $-27M | $-24M | -42.3% |
| Dec 2022 | $63M | -23.0% | $-19M | $-41M | -65.6% |
| Dec 2021 | $81M | -20.4% | $4M | $1M | 1.1% |
| Dec 2020 | $102M | +12.8% | $0M | $-6M | -6.3% |
| Dec 2019 | $90M | -6.8% | $-24M | $-29M | -32.0% |
| Dec 2018 | $97M | -2.1% | $-20M | $-22M | -22.8% |
| Dec 2017 | $99M | — | $-38M | $-40M | -40.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-4M | $0M | $-5M | — | — |
| Dec 2023 | $-12M | $1M | $-12M | — | — |
| Dec 2022 | $-1M | $1M | $-2M | — | — |
| Dec 2021 | $13M | $2M | $11M | — | — |
| Dec 2020 | $24M | $3M | $21M | — | — |
| Dec 2019 | $5M | $2M | $3M | — | — |
| Dec 2018 | $7M | $8M | $-0M | — | — |
| Dec 2017 | $9M | $5M | $4M | — | — |
SEC filings
- Nov 12, 20266-KReport of foreign issuer
- Oct 5, 20266-KReport of foreign issuer
- Sep 9, 20266-KReport of foreign issuer
- Sep 8, 20266-KReport of foreign issuer
- Aug 28, 20266-KReport of foreign issuer
- Aug 17, 20266-KReport of foreign issuer
- Aug 14, 20266-KReport of foreign issuer
- Jul 22, 20266-KReport of foreign issuer
- Jul 22, 20266-KReport of foreign issuer
- Jul 2, 20266-KReport of foreign issuer
- Jun 30, 20266-KReport of foreign issuer
- Jun 29, 20266-KReport of foreign issuer
Official filings of Trinity Biotech PLC with the US Securities and Exchange Commission.
Annual results
- Revenue
- $62 M
- Operating income
- $-21 M
- Net income
- $-32 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $103 M
- Total liabilities
- $138 M
- Total equity
- $-35 M
As of December-2024
Top 10 institutional investors in Trinity Biotech PLC#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Hunter Associates Investment Management LLC | 24,637 | New | 3.57% | $0 M | Oct 26, 2026 |
| 2 | Colonial Trust Advisors | 350 | New | 0.05% | $0 M | Nov 10, 2026 |
| 3 | Jones Financial Companies Lllp | 331 | New | 0.05% | $0 M | Nov 13, 2026 |
| 4 | Rhumbline Advisers | 311 | New | 0.05% | $0 M | Nov 10, 2026 |
| 5 | UBS Group AG | 171 | New | 0.02% | $0 M | Nov 10, 2026 |
| 6 | Osaic Holdings, Inc. | 149 | New | 0.02% | $0 M | Nov 12, 2026 |
| 7 | Wells Fargo & Company/mn | 83 | New | 0.01% | $0 M | Nov 16, 2026 |
| 8 | Morgan Stanley | 66 | New | 0.01% | $0 M | Nov 13, 2026 |
| 9 | Farther Finance Advisors, LLC | 66 | New | 0.01% | $0 M | Oct 8, 2026 |
| 10 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Markets and events: Trinity Biotech PLC#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-11-05 16:18 UTC, code LUDP, resumed 16:23 UTC
- 2026-10-01 16:13 UTC, code LUDP, resumed 16:18 UTC
- 2026-07-23 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-08-14 14:25 UTC, code LUDP, resumed 14:30 UTC
Fails to deliver
- : 9 shares at $7.15
- : 625 shares at $7.31
- : 341 shares at $7.67
- : 284 shares at $7.89
- : 293 shares at $7.78
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Trinity Biotech PLC scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in growth (1 of 5), weakest in profitability (0 of 4). Fiscal year 2024; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 5
- ✓Revenue grew in the newest year8.3%Revenue up 8.3% in fiscal 2024.
- ✗Revenue up more than 5% a year over three years-8.8%-8.8% a year over the three years to fiscal 2024.
- ✗Faster growth over three years than its peers' median-8.8%-8.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$32 M-$32 M in fiscal 2024 against -$29 M in 2019.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2024.
Profitability0 of 4
- ✗Profitable in the newest year-$32 MNet income -$32 M in fiscal 2024.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
- ✗Operating margin above its peers' median-34.4%-34.4% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-34.4%-34.4% in fiscal 2024 against 4.9% in 2021.
Financial health1 of 2
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $5 M at the end of fiscal 2024.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Trinity Biotech PLC's statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -34.4% | -2.4% | |
| Net margin | -51.6% | -3.6% | |
| Revenue growth, 3 years a year | -8.8% | 3.6% | |
| Revenue growth | 8.3% | 6.6% | |
| Free cash flow margin | -7.5% | 4.7% |
4of 8on the Piotroski tests of financial strength
- Net loss of $32 million, the 3th loss-making year in a row.
- Free cash flow was negative: -$5 million.
- Shareholders' equity is negative: -$35 million.
- More cash than debt: net cash of $5 million.
Trinity Biotech PLC: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 62+8.3%100% | 57−9.1%100% | 63r75−23.0%100% | 81r93−20.4%100% | 102+12.8%100% | 90−6.8%100% | 97−2.1%100% | 99−0.5%100% | 100−0.6%100% | 100—100% | |
| Cost of revenue | 40+7.3%65.2% | 37−17.4%65.8% | 45r53−5.1%72.4% | 48r55−10.7%58.8% | 53+2.1%52.4% | 52−5.9%57.8% | 56−2.9%57.3% | 57+2.0%57.7% | 56+4.6%56.3% | 54—53.6% | |
| Gross profit | 21+10.2%34.8% | 19+12.6%34.2% | 17r22−48.4%27.6% | 33r38−31.1%41.2% | 49+27.4%47.6% | 38−8.0%42.2% | 41−1.1%42.7% | 42−3.7%42.3% | 43−6.5%43.7% | 47—46.4% | |
| Research and development | 4.5+3.7%7.4% | 4.4+5.8%7.7% | 4.1−8.0%6.6% | 4.5−11.5%5.5% | 5.1−4.6%5.0% | 5.3−0.8%5.9% | 5.4−5.1%5.5% | 5.7+12.2%5.7% | 5.0−0.6%5.1% | 5.1—5.1% | |
| Selling, general and administrative | 29−7.5%46.8% | 31+15.5%54.8% | 27r29+19.9%43.2% | 23r25−14.7%27.7% | 26−4.6%25.9% | 28−6.2%30.6% | 29−8.6%30.4% | 32+6.2%32.5% | 30+7.6%30.5% | 28—28.2% | |
| Operating income | −21—−34.4% | −27—−47.6% | −19r−17−591%−30.9% | 3.9r6.6+4702%4.9% | 0.1—0.1% | −24—−26.7% | −20—−20.8% | −38—−38.0% | −40−395%−40.0% | 14—13.5% | |
| Interest and finance income | 0−100%0.0% | 1.2+286%2.1% | 0.3−75.2%0.5% | 1.2+3297%1.5% | 0.0−94.8%0.0% | 0.7−67.2%0.8% | 2.1−33.6%2.2% | 3.2+1.6%3.2% | 3.1−76.7%3.2% | 13—13.5% | |
| Interest expense and finance costs | 9.6−13.5%15.5% | 11−55.3%19.4% | 25r25+249%39.6% | 7.1r7.1+4.9%8.7% | 6.8+2.6%6.6% | 6.6+29.6%7.3% | 5.1−6.0%5.2% | 5.4−0.6%5.5% | 5.4+34.2%5.5% | 4.1—4.0% | |
| Income before tax | −31—−49.9% | −37—−65.0% | −44r−41—−70.0% | −1.9r0.8—−2.4% | −6.6—−6.5% | −30—−33.2% | −23—−23.9% | −40—−40.2% | −42−284%−42.3% | 23—22.9% | |
| Income tax | 0.5—0.8% | −0.1—−0.1% | −0.2r−0.2—−0.3% | −0.1r−0.2—−0.1% | −0.6—−0.6% | −1.0—−1.1% | −0.5—−0.5% | −1.2—−1.2% | −3.6−571%−3.6% | 0.8—0.8% | |
| Income from continuing operations | −31—−50.7% | −37—−64.9% | −44r−41—−69.7% | −1.9r0.9—−2.3% | −6.0—−5.9% | −29—−32.1% | −23—−23.4% | −39—−39.0% | −39−274%−38.7% | 22—22.1% | |
| Income from discontinued operations | −0.6−104%−0.9% | 13+399%22.6% | 2.6r−0.0−5.4%4.1% | 2.7r−0.1—3.4% | −0.4−587%−0.4% | 0.1−86.4%0.1% | 0.6—0.6% | −1.6—−1.6% | −62—−62.3% | — | |
| Net income including minority interests | −31—−50.7% | −37—−64.9% | −44r−41—−69.7% | −1.9r0.9—−2.3% | −6.0—−5.9% | −29—−32.1% | −23—−23.4% | −39—−39.0% | −39−274%−38.7% | 22—22.1% | |
| Net income attributable to shareholders | −32—−51.6% | −24—−42.3% | −41−4787%−65.6% | 0.9—1.1% | −6.4—−6.3% | −29—−32.0% | −22—−22.8% | −40—−40.6% | −101−562%−101% | 22—21.8% | |
| Shares, weighted average (basic) | 359+135%— | 153+13.5%— | 135+61.4%— | 840.0%— | 840.0%— | 84−0.0%— | 84−3.3%— | 86−5.8%— | 92−0.9%— | 93—— | |
| Shares, weighted average (diluted) | — | — | 80+115%— | 37r107−2.0%— | 38r105−62.9%— | 102−1.6%— | 104−3.7%— | 108−5.0%— | 113+3.3%— | 110—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.2+40.0%5.0% | 3.7−43.9%6.2% | 6.6−74.6%7.1% | 26−5.2%21.8% | 27+79.4%21.0% | 15−49.7%11.6% | 30−47.4%20.0% | 58r24−25.3%29.9% | 77−24.4%30.9% | 102—— | |
| Receivables | 16+15.6%15.6% | 14−11.8%23.4% | 16−2.3%17.1% | 16−28.9%13.6% | 23+8.0%17.4% | 21−14.1%16.0% | 24+17.8%16.1% | 21−8.2%10.7% | 23—9.0% | — | |
| Inventory | 19−2.8%18.8% | 20−11.4%33.5% | 23−22.7%24.4% | 29−3.6%24.5% | 30−5.6%23.2% | 32+5.5%24.4% | 30−7.5%20.0% | 33+0.7%17.0% | 33—13.1% | — | |
| Current assets | 41+5.3%39.8% | 39−16.3%65.7% | 47−35.8%50.7% | 73−12.7%61.1% | 83+16.7%63.9% | 71−17.6%54.5% | 87−23.0%57.1% | 113−15.7%58.3% | 133—53.5% | — | |
| Property, plant and equipment | 4.6+144%4.5% | 1.9−66.7%3.2% | 5.7−4.0%6.2% | 5.9−30.8%5.0% | 8.5−8.0%6.6% | 9.3+73.3%7.1% | 5.4−7.6%3.5% | 5.8−56.7%3.0% | 13—5.4% | — | |
| Right-of-use (leased) assets | — | — | — | — | — | 5.2−48.2%4.0% | 10—6.7% | — | — | — | |
| Non-current assets | 62+205%60.2% | 20−55.1%34.3% | 45−1.7%49.3% | 46−1.9%38.9% | 47−21.1%36.1% | 60−8.2%45.5% | 65−19.1%42.9% | 80−30.8%41.7% | 116—46.5% | — | |
| Total assets | 103+73.8%100% | 59−35.5%100% | 92−22.5%100% | 119−8.8%100% | 130−0.5%100% | 131−13.6%100% | 152−21.4%100% | 193−22.7%100% | 250—100% | — | |
| Accounts payable | 6.8+75.9%6.6% | 3.9−37.4%6.5% | 6.2−8.3%6.7% | 6.8−4.8%5.7% | 7.1−9.3%5.4% | 7.8−3.5%6.0% | 8.1+0.9%5.4% | 8.0−10.8%4.2% | 9.0—3.6% | — | |
| Current liabilities | 32+113%31.1% | 15−13.3%25.3% | 17−82.7%18.8% | 100+271%84.5% | 27+39.1%20.8% | 19+10.5%14.8% | 18−17.1%11.6% | 21−16.0%11.0% | 25—10.1% | — | |
| Long-term debt | 0.20.0%0.2% | 0.20.0%0.4% | 0.2−99.7%0.2% | 83+0.8%70.1% | 83r83+0.8%63.4% | 82+0.8%62.6% | 81−12.5%53.7% | 93+0.8%48.2% | 92+0.8%37.0% | 92—— | |
| Non-current liabilities | 106+55.6%103% | 68−11.2%115% | 77+311%83.5% | 19−82.3%15.7% | 106−1.3%81.0% | 107+18.8%81.6% | 90−15.5%59.3% | 107−7.8%55.2% | 116—46.3% | — | |
| Total liabilities | 138+66.1%134% | 83−11.6%140% | 94−20.9%102% | 119−10.1%100% | 133+5.0%102% | 126+17.4%96.4% | 108−15.8%71.0% | 128−9.3%66.2% | 141—56.4% | — | |
| Retained earnings | −79—−76.6% | −49—−81.8% | −27−313%−29.0% | 13+18.8%10.6% | 11−34.5%8.1% | 16−70.8%12.3% | 55−27.0%36.5% | 76−31.4%39.3% | 110—44.2% | — | |
| Total equity | −35—−34.1% | −24—−40.3% | −2.2—−2.4% | −0.3—−0.3% | −2.2−147%−1.7% | 4.7−89.3%3.6% | 44−32.4%29.0% | 65−40.0%33.8% | 109−49.2%43.6% | 214—— | |
| Total liabilities and equity | 103+73.8%100% | 59−35.5%100% | 92−22.5%100% | 119−8.8%100% | 130−0.5%100% | 131−13.6%100% | 152−21.4%100% | 193−22.7%100% | 250—100% | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2—0.3% | 0—0.0% | 0−100%0.0% | 38r0.0+94900%46.8% | 0.0+900%0.0% | 0.0−94.9%0.0% | 0.1−85.0%0.1% | 0.5+27.5%0.5% | 0.4+509%0.4% | 0.1—0.1% | |
| Share-based compensation | 1.3−36.4%2.1% | 2.1+17.9%3.6% | 1.8+59.5%2.8% | 1.1+38.9%1.4% | 0.8+4.5%0.8% | 0.8−44.6%0.8% | 1.4+47.5%1.4% | 0.9−34.4%0.9% | 1.4−8.8%1.4% | 1.6—1.5% | |
| Cash from operating activities | −4.2—−6.8% | −12—−20.3% | −0.9−107%−1.5% | 13−44.3%16.3% | 24+339%23.3% | 5.4−25.1%6.0% | 7.2−21.8%7.4% | 9.3−9.6%9.3% | 10−22.3%10.3% | 13—13.1% | |
| Capital expenditure | −0.4—−0.7% | −0.8—−1.4% | −1.1—−1.8% | −1.8—−2.2% | −3.2—−3.1% | −2.1—−2.3% | −7.5—−7.8% | −4.8—−4.9% | −4.2—−4.2% | −7.1—−7.1% | |
| Intangible assets bought | −9.7—−15.7% | −1.9—−3.3% | −4.9—−7.8% | −6.9—−8.5% | −7.0—−6.9% | −9.7—−10.7% | −9.9—−10.2% | −10—−10.3% | −17—−16.6% | −19—−19.5% | |
| Cash from investing activities | −23−193%−37.3% | 25—43.6% | −6.0—−9.6% | −8.7—−10.7% | −10—−10.0% | −12—−13.1% | −17—−17.9% | −16—−16.3% | −22—−22.0% | −28—−27.6% | |
| Debt issued | 30—49.0% | 0—0.0% | 0−100%0.0% | 1.8−61.0%2.2% | 4.5—4.4% | 0—0.0% | — | — | — | — | |
| Debt repaid | 0—0.0% | −10—−17.7% | −35—−55.2% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Shares issued | 7.4—12.0% | 0−100%0.0% | 25—40.5% | 0—0.0% | 0—0.0% | — | — | — | 0.9−70.9%0.9% | 2.9—2.9% | |
| Shares bought back | — | — | — | — | — | — | −0.4—−0.4% | −7.8—−7.9% | −9.3—−9.4% | — | |
| Dividends paid | — | — | — | — | — | — | — | — | — | −5.1—−5.1% | |
| Cash from financing activities | 29—46.8% | −16—−28.2% | −12—−19.7% | −6.0—−7.4% | −2.7—−2.7% | −7.5—−8.3% | −17—−17.4% | −13—−12.8% | −13−112%−13.4% | 108—107% | |
| Exchange-rate effect on cash | −0.2—−0.3% | −0.0—−0.1% | −0.1−304%−0.2% | 0.1−36.0%0.1% | 0.1−2.3%0.1% | 0.1—0.1% | −0.3−517%−0.3% | 0.1−55.1%0.1% | 0.2—0.2% | −0.1—−0.1% | |
| Change in cash | 1.7—2.7% | −2.8—−5.0% | −19—−30.7% | −1.5−114%−1.8% | 11—10.6% | −14—−15.4% | −27—−27.9% | −20—−19.7% | −25−127%−25.1% | 93—92.8% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Trinity Biotech PLC sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Clinical laboratory goods$32 M72%-20%
- Point-of-Care$8 M19%-54%
- Clinical laboratory services$4 M9.2%-16%
Countries and regions
- Americas – unused tax losses$25 M56%-18%
- Asia / Africa$15 M35%-38%
- 🇮🇪 Ireland$15 M34%-27%
- Europe (including Ireland)$4 M8.6%-45%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
How Trinity Biotech PLC compares in Diagnostics and Research
- Market cap$8 M · higher than 11% of 110
- Revenue$62 M · higher than 29% of 123
- Net margin-51.6% · higher than 15% of 112
- Revenue growth8.3% · higher than 59% of 89
- Price / sales0.1× · lowest of 85
- FCF yield-57.4% · higher than 12% of 66
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Trinity Biotech PLC🇮🇪 | $8 M | — | -51.6% | +8.3% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Trinity Biotech PLC? Verify and update this profile — free
Show Trinity Biotech PLC's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.